


RECEIVED

NOV 27 2000

TECH CENTER 1600/2900

9. A compound having the following formula:



10. A method for treating urinary incontinence comprising administering to a patient in need thereof a therapeutically effective amount of the compound of claim 9 or a pharmaceutically acceptable salt thereof.

REMARKS

Applicants confirm the election of a single distinct compound for purposes of examination as indomethacin 3-nitroxymethyl-phenyl ester, which formula is given at page 46 of the specification, and the chemical synthesis thereof is detailed at page 45. Applicants, if required, confirm the election of the disclosed composition for local infusion containing 5 mg/kg of the above ester identified as: NO-I at page 45, line 8, of the specification, in a physiological solution as disclosed in the last row of Table 2 and lines 3-4 of page 52.

RECEIVED

NOV 27 2000


TECH CENTER 1600/2900

By the above amendments applicants are presenting correctly numbered claims. That is, identifying new claims 3 and 4 in the amendment filed October 26 was in error. The claims should have been presented as new 7 and 8. The undersigned apologizes for any inconvenience to the Examiner.

Accordingly, an early examination and an early action on the merits are respectfully requested. In the event this paper is not considered to be timely filed, Applicants respectfully petition for an appropriate extension of time. Any fees for such an extension, together with any additional fees which may be due with respect to this paper, may be charged to our Deposit Account No.01-2300.

Respectfully submitted,

ARENT FOX KINTNER PLOTKIN & KAHN, PLLC


James A. Poulos, III
Attorney for Applicants
Registration No. 31,714

1050 Connecticut Avenue, NW, Suite 600
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

POU:kga